Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

About

Company description

Xellia is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.

Xellia is wholly owned by Novo Holdings A/S.

Production Sites: Five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China and in the U.S.
Expertise: Xellia has over 100 years’ experience in the development, manufacture and supply of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Xellia is the leading supplier of the important anti-infectives Vancomycin and Colistimethate Sodium (CMS).

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Antibiotics |Generic APIs |Finished Dosage Forms More

Upcoming events

13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 1F21 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 90G10 See our Exhibitor Profile   See full Exhibitor List

Categories affiliated with Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

Contact information

Address

Telephone

Website

View all contact information